EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

Overview of attention for article published in Journal of Clinical Oncology, February 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 2 news outlets
policy: 1 policy source
twitter: 12 X users

patent: 1 patent
guideline: 1 clinical guideline source
podcasts: 2 podcasts

Readers on

mendeley: 210 Mendeley

So far, Altmetric has seen 2 news stories from 2 outlets.

A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin

Pharmacy Times, 06 Nov 2025

Abstract The recognition of enfortumab vedotin-ejfv (EV) as an effective therapeutic in urothelial carcinoma (UC) is supported…

Nectin-4 Emerges as a Therapeutic Target in Urothelial Carcinoma and Beyond

OncLive, 02 Jan 2022

Most ongoing clinical trials exploring nectin-4 as a target involve studies of enfortumab vedotin and its potential synergy…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.